Is ICNAF or MRK a better dividend investment in 2026?

ICNAF currently yields 3636.36% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: ICNAF offers higher current income.

What is the dividend yield difference between ICNAF and MRK?

ICNAF has a forward dividend yield of 3636.36% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 3633.60 percentage points.

Home › Compare › ICNAF vs MRK

ICNAF vs MRK: Dividend Comparison 2026

ICNAF yields 3636.36% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ICNAF wins by $2866463184412.29M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ICNAF

● Live price

3636.36%

Share price

$0.06

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2866463184412.34M

Annual income

$2,719,355,147,267,598,000.00

Full ICNAF calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — ICNAF vs MRK

📍 ICNAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ICNAF	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ICNAF + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ICNAF pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICNAF

Annual income on $10K today (after 15% tax)

$309,090.91/yr

After 10yr DRIP, annual income (after tax)

$2,311,451,875,177,458,000.00/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, ICNAF beats the other by $2,311,451,875,177,450,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICNAF + MRK for your $10,000?

ICNAF: 50%MRK: 50%

100% MRK50/50100% ICNAF

Portfolio after 10yr

$1433231592206.20M

Annual income

$1,359,677,573,633,803,800.00/yr

Blended yield

94.87%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ICNAF

No analyst data

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICNAF buys

MRK buys

No recent congressional trades found for ICNAF or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricICNAFMRK

Forward yield	3636.36% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$2866463184412.34M ✓	$56.8K
Annual income after 10y	$2,719,355,147,267,598,000.00 ✓	$9,798.13
Total dividends collected	$2856387447109.89M ✓	$28.9K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: ICNAF vs MRK ($10,000, DRIP)

Year	ICNAF Portfolio	ICNAF Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$374,336	$363,636.36	$11,206	$366.19	+$363.1K → ICNAF
2	$13,122,252	$12,721,711.59	$12,650	$502.35	+$13.11M → ICNAF
3	$430,821,997	$416,781,187.80	$14,407	$694.19	+$430.81M → ICNAF
4	$13,249,309,769	$12,788,330,232.42	$16,585	$967.82	+$13249.29M → ICNAF
5	$381,734,397,300	$367,557,635,846.92	$19,342	$1,363.89	+$381734.38M → ICNAF
6	$10,305,595,787,232	$9,897,139,982,121.38	$22,913	$1,947.19	+$10305595.76M → ICNAF
7	$260,738,028,023,917	$249,711,040,531,578.75	$27,662	$2,823.89	+$260738028.00M → ICNAF
8	$6,183,518,404,581,653	$5,904,528,714,596,061.00	$34,159	$4,173.35	+$6183518404.55M → ICNAF
9	$137,484,146,864,247,860	$130,867,782,171,345,470.00	$43,337	$6,308.80	+$137484146864.20M → ICNAF
10	$2,866,463,184,412,343,000	$2,719,355,147,267,598,000.00	$56,776	$9,798.13	+$2866463184412.29M → ICNAF

ICNAF vs MRK: Complete Analysis 2026

ICNAF — Stock

Icanic Brands Company Inc. operates as a cannabis branded products manufacturer in California and Nevada. It offers X-Sprays, an oral spray product for overall health and well-being, as well as general lifestyle. The company provides hemp based cannabidiol and non-cannabidiol infusion sprays, as well as infused pre-rolls. In addition, it offers products under the Ganja gold brand name. The company was formerly known as Integrated Cannabis Company, Inc. Icanic Brands Company Inc. is headquartered in Vancouver, Canada.

Full ICNAF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this ICNAF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICNAF vs SCHD ICNAF vs JEPI ICNAF vs O ICNAF vs KO ICNAF vs MAIN ICNAF vs JNJ ICNAF vs ABBV ICNAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.